Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LJ2S
|
|||
| Drug Name |
Anti-NY-ESO-1 CAR-T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Esophageal cancer [ICD-11: 2B70] | Phase 1/2 | [1] | |
| Lung cancer [ICD-11: 2C25.0; ICD-9: 162] | Phase 1/2 | [1] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [1] | ||
| Synovial sarcoma [ICD-11: 2B5A; ICD-9: 171] | Phase 1/2 | [1] | ||
| Company |
Shenzhen BinDeBio Ltd.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cancer/testis antigen 1 (NY-ESO-1) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.